What factors should be paid attention to when discontinuing brigatinib?

Brigatinib (Brigatinib), as a treatment for ALK -positive non-small cell lung cancer (NSCLC), usually requires patients to take it for a long time until the disease is effectively controlled or adverse reactions occur. However, the specific duration of medication is not set in stone and is affected by many factors, including drug efficacy and patient tolerance.

During treatment, patients need to undergo regular imaging examinations and clinical evaluations so that doctors can monitor the progression of the disease and the effectiveness of the drugs. These assessments are critical in determining whether brigatinib (brigatinib) is still effective. If the patient's condition remains stable and side effects are acceptable, the drug is usually continued to maximize progression-free survival (PFS) and maintain disease control.

However, the use of brigatinib may also be associated with a range of side effects, such as nausea, fatigue, and high blood sugar. If a patient develops serious side effects, such as interstitial lung disease (ILD) or severe high blood pressure, the doctor may consider adjusting the dose of the drug or temporarily discontinuing the drug. In addition, as treatment progresses, some patients may develop resistance to brigatinib , which may manifest as worsening of the disease or a weakening of the tumor's response to the drug. In this case, the doctor may consider switching to other treatments or regimens.

Therefore, the duration of use of brigatinib varies among individuals and may be affected by a variety of factors. In order to ensure the safe use of drugs and optimize treatment effects, patients need to maintain close communication with their doctors, regularly evaluate their condition, and promptly adjust their treatment plan when drug resistance or serious side effects occur. In this way, patients can better manage their disease and maximize the therapeutic benefits of brigatinib (brigatinib) for as long as possible.